Top 20 Medical Device Companies of 2026
Shots:
The global medical devices market is entering a new era of transformation, powered by AI-driven diagnostics, robotic surgery, cardiovascular breakthroughs, and minimally invasive innovation. Valued at $572.31B in 2025, the market is racing toward the $1T milestone by 2034. In FY2025, Medtronic dominated with $35.48B in revenue,…
TOP 20
Shots:
PharmaShots Awards 2026 celebrates the industry’s most influential innovators across biopharma, MedTech, diagnostics, generics, nutraceuticals, animal health, digital health, and AI-driven drug discovery spotlighting organizations redefining the future of global healthcare.
From Eli Lilly, Pfizer, and AbbVie to Medtronic, Roche, Siemens Healthineers, and XtalPi, this year’s awardees exemplify scientific excellence, breakthrough innovation, and a relentless commitment to…
Shots:
Biopharma dealmaking in 2025 continued to face significant headwinds, with collaborations frequently collapsing due to strategic reprioritization, fierce competitive pressures, unfavorable clinical readouts, and failure to meet key closing conditions highlighting the inherent uncertainty and capital risk embedded in innovation-driven partnerships
The year underscored a clear dominance of R&D-focused collaborations and licensing agreements,…
Shots:
The biopharma industry is a multi-hundred-billion-dollar market, with a projected compound annual growth rate (CAGR) of 8.6%, the global biopharma market is expected to reach $1.41T by 2034. Eli Lilly and Co. ranked first with $65.17B, followed by Pfizer ($61.19B) and AbbVie ($61.16B), reflecting strong market concentration among large-cap innovators with diversified, high-value portfolios …
Shots:
The Healthcare IPOs in 2025 underscore sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare companies, signaling robust capital deployment into next-generation therapies, advanced diagnostics, and evolving healthcare delivery models worldwide.
IPO activity was dominated by high-value raises, with Medline Industries ($7.2B) leading by a wide margin, followed by Caris Life Sciences…
Shots:
From AI-powered discovery to next-generation biologics and gene editing, 2025 was a blockbuster year for life sciences dealmaking. Pharma and biotech companies signed multibillion-dollar partnerships and acquisitions to accelerate innovation across oncology, cardiometabolic diseases, neurology, and rare disorders.
Platform technologies dominated the deal landscape, with big pharma securing access to cutting-edge modalities from bispecific…
Shots:
Women leaders are reshaping the healthcare industry, bringing visionary leadership, scientific expertise, and strategic insight to traditionally male-dominated spaces
From biotech innovation to global pharmaceutical enterprises, these trailblazers are driving transformative solutions, advancing patient care, and championing inclusive workplace cultures
PharmaShots spotlights 20 extraordinary women leaders in healthcare, celebrating their achievements, impact, and inspiring journeys that…
Shots:
The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.
Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…
Top 20 Emerging Animal Health Companies Worldwide in 2026
Shots:
Emerging companies in the animal health sector are gaining ground in livestock, poultry, equine, and companion animal markets. Small and mid-sized innovators offer affordable care models, targeted biologics, and sustainable solutions for global needs
These firms bolster their positions via portfolio growth, partnerships, acquisitions, and…
Shots:
2025 pharma M&A was defined by fewer but more transformational deals, with companies prioritizing commercial-stage assets, late-stage pipelines, and platform technologies capable of reshaping long-term growth and strengthening core therapeutic franchises
The year’s momentum was led by three standout transactions, J&J’s $14.6B acquisition of Intra-Cellular Therapies, Novartis’ $12B deal for Avidity Biosciences, and Merck’s…

